Cargando…

Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment

BACKGROUND: Recently approved second‐generation androgen receptor inhibitors (SGARIs) for non‐metastatic castration‐resistant prostate cancer (nmCRPC) have similar efficacy but differ in safety profiles. We used a discrete choice experiment (DCE) to examine how nmCRPC patients and caregivers perceiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Srinivas, Sandy, Mohamed, Ateesha F., Appukkuttan, Sreevalsa, Botteman, Marc, Ng, Xinyi, Joshi, Namita, Tsai, Jui‐Hua, Fang, Jarjieh, Waldeck, A. Reginald, Simmons, Stacey J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520320/ https://www.ncbi.nlm.nih.gov/pubmed/32725755 http://dx.doi.org/10.1002/cam4.3321

Ejemplares similares

Physician preferences for non-metastatic castration-resistant prostate cancer treatment
por: Srinivas, Sandy, et al.
Publicado: (2020)

Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer
por: Appukkuttan, Sreevalsa, et al.
Publicado: (2021)

Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States
por: Hussain, Arif, et al.
Publicado: (2022)

Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer
por: Rasmussen, Kelli M., et al.
Publicado: (2023)

Understanding what matters to metastatic castration‐resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey
por: George, Daniel J., et al.
Publicado: (2022)

Clinical outcomes, management, and treatment patterns in patients with metastatic castration‐resistant prostate cancer treated with radium‐223 in community compared to academic settings
por: Sartor, Oliver, et al.
Publicado: (2021)

A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use
por: Appukkuttan, Sreevalsa, et al.
Publicado: (2019)

Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center
por: McKay, Rana R., et al.
Publicado: (2020)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Understanding Treatment Strategies and Preferences in Nonmetastatic Castration-Resistant Prostate Cancer From the Japanese Physician Perspective
por: Suzuki, Kazuhiro, et al.
Publicado: (2021)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2022)

Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
por: Schultz, Neil M., et al.
Publicado: (2020)

National Cancer Database report of nonmetastatic esophageal small cell carcinoma
por: Verma, Vivek, et al.
Publicado: (2018)

Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
por: Rhea, Logan P, et al.
Publicado: (2019)

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2022)

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2023)

Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors
por: Qian, Yi, et al.
Publicado: (2016)

Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma
por: Shao, Yanxiang, et al.
Publicado: (2019)

Utilization of short-course radiation therapy for patients with nonmetastatic rectal adenocarcinoma in the United States
por: Abdel-Rahman, Omar, et al.
Publicado: (2018)

Denosumab: Delay of bone metastasis in men with nonmetastatic castrate-resistant prostate cancer
por: Manger, Jules P., et al.
Publicado: (2012)

Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity
por: López-Campos, Fernando, et al.
Publicado: (2021)

Time‐dependent and nonlinear effects of prognostic factors in nonmetastatic colorectal cancer
por: Chi, Sheng‐Qiang, et al.
Publicado: (2017)

The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer
por: Gruhl, Joshua D., et al.
Publicado: (2020)

Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population‐based study
por: Bao, Shengnan, et al.
Publicado: (2021)

Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer
por: Ogita, Shin, et al.
Publicado: (2012)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease
por: Henriquez, Ivan, et al.
Publicado: (2021)

Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2021)

Significance of delayed primary excision in localized nonmetastatic adult head and neck rhabdomyosarcoma
por: Kobayashi, Kenya, et al.
Publicado: (2016)

Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer
por: Hakozaki, Yuji, et al.
Publicado: (2022)

Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy
por: Kool, Ronald, et al.
Publicado: (2021)

Plasma and Urine Free Glycosaminoglycans as Monitoring Biomarkers in Nonmetastatic Renal Cell Carcinoma—A Prospective Cohort Study
por: Gatto, Francesco, et al.
Publicado: (2022)

Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis
por: Huntington, Scott F., et al.
Publicado: (2022)

Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer
por: Kanematsu, Masako, et al.
Publicado: (2015)

Factors associated with cognitive impairment during the first year of treatment for nonmetastatic breast cancer
por: Rodriguez, Nicole, et al.
Publicado: (2021)

Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2022)

Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
por: Saad, Fred, et al.
Publicado: (2021)

Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
por: Feng, Felix Y., et al.
Publicado: (2021)

Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma
por: Piccinelli, Mattia L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5bcso0qs80j8bql21je6g8tl04